SignalCorporate
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
$200M oversubscribed offering plus clinical data and partnership milestone signal multiple catalysts.
Context
What happened: Recursion announced a $200 million oversubscribed follow-on offering with healthcare investors, plus clinical updates for REC-4881 in FAP and REC-1245, and a Sanofi partnership milestone.
Key numbers: $200 million offering.
Why it matters: The financing and data support Recursion's pipeline momentum, with a registrational trial targeted for 2H 2027 pending FDA discussions and Sanofi optioning a development candidate from their collaboration.
Market: +1.9% today ($16.13), 0.1x vol — as of 15:47 UTC
What changed
Recursion announced a $200 million oversubscribed follow-on offering with healthcare investors, plus clinical updates for REC-4881 in FAP and REC-1245, and a Sanofi partnership milestone.
Why it matters
The financing and data support Recursion's pipeline momentum, with a registrational trial targeted for 2H 2027 pending FDA discussions and Sanofi optioning a development candidate from their collaboration.
Market: +1.9% today ($16.13), 0.1x vol — as of 15:47 UTC